Don Hayes1,2, Bryan A Whitson3, Samir N Ghadiali4,5, Joseph D Tobias6,7, Heidi M Mansour8, Sylvester M Black3. 1. Section of Pulmonary Medicine, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, 700 Children's Drive, Columbus, OH, 43205, USA. hayes.705@osu.edu. 2. Department of Internal Medicine, The Ohio State University, Columbus, OH, USA. hayes.705@osu.edu. 3. Department of Surgery, The Ohio State University, Columbus, OH, USA. 4. Department of Internal Medicine, The Ohio State University, Columbus, OH, USA. 5. Department of Biomedical Engineering, The Ohio State University, Columbus, OH, USA. 6. Department of Anesthesiology, The Ohio State University, Columbus, OH, USA. 7. Department of Anesthesiology and Pain Medicine, Nationwide Children's Hospital, Columbus, OH, USA. 8. Skaggs Pharmaceutical Sciences Center, The University of Arizona College of Pharmacy, Tucson, AZ, USA.
Abstract
BACKGROUND: Data on human leukocyte antigen (HLA) mismatching and survival after lung transplantation (LTx) are variable. METHODS: The UNOS database was queried from 1987 to 2013 to examine survival associated with total HLA mismatch ≥3 and mismatches of 2 at A, B, and DR loci. RESULTS: Of 23,528 first-time, adult LTx recipients, 23,384 were included in the univariate Cox analysis, 19,944 in the Kaplan-Meier survival function evaluation, and 16,224 in the multivariate Cox models. Adjusted models found that the total HLA mismatch ≥3 increased the mortality hazard [hazard ratio (HR) 1.214; 95% confidence interval (95% CI) 1.073, 1.374; p = 0.002]. Both HLA-A (HR 1.070; 95% CI 1.023, 1.119; p = 0.003) and HLA-DR (HR 1.053; 95% CI 1.007, 1.101; p = 0.024) were associated with increased mortality risk, but HLA-B (HR 1.006; 95% CI 0.958, 1.056; p = 0.805) was not. Older age, higher creatinine, and higher body mass index were associated with increased risk for death. More recent lung transplant and longer ischemic time were associated with reduced mortality risk. Induction with basiliximab at time of transplant was beneficial by significantly decreasing the risk of death (HR 0.846; 95% CI 0.786, 0.909; p < 0.001). CONCLUSIONS: HLA mismatching is associated with increased hazard risk for death after LTx, while induction with basiliximab and other factors related to LTx reduce the risk.
BACKGROUND: Data on human leukocyte antigen (HLA) mismatching and survival after lung transplantation (LTx) are variable. METHODS: The UNOS database was queried from 1987 to 2013 to examine survival associated with total HLA mismatch ≥3 and mismatches of 2 at A, B, and DR loci. RESULTS: Of 23,528 first-time, adult LTx recipients, 23,384 were included in the univariate Cox analysis, 19,944 in the Kaplan-Meier survival function evaluation, and 16,224 in the multivariate Cox models. Adjusted models found that the total HLA mismatch ≥3 increased the mortality hazard [hazard ratio (HR) 1.214; 95% confidence interval (95% CI) 1.073, 1.374; p = 0.002]. Both HLA-A (HR 1.070; 95% CI 1.023, 1.119; p = 0.003) and HLA-DR (HR 1.053; 95% CI 1.007, 1.101; p = 0.024) were associated with increased mortality risk, but HLA-B (HR 1.006; 95% CI 0.958, 1.056; p = 0.805) was not. Older age, higher creatinine, and higher body mass index were associated with increased risk for death. More recent lung transplant and longer ischemic time were associated with reduced mortality risk. Induction with basiliximab at time of transplant was beneficial by significantly decreasing the risk of death (HR 0.846; 95% CI 0.786, 0.909; p < 0.001). CONCLUSIONS: HLA mismatching is associated with increased hazard risk for death after LTx, while induction with basiliximab and other factors related to LTx reduce the risk.
Authors: Chad A Witt; Joseph P Gaut; Roger D Yusen; Derek E Byers; Jennifer A Iuppa; K Bennett Bain; G Alexander Patterson; Thalachallour Mohanakumar; Elbert P Trulock; Ramsey R Hachem Journal: J Heart Lung Transplant Date: 2013-08-13 Impact factor: 10.247
Authors: S Sundaresan; T Mohanakumar; M A Smith; E P Trulock; J Lynch; D Phelan; J D Cooper; G A Patterson Journal: Transplantation Date: 1998-03-15 Impact factor: 4.939
Authors: Andrew E Gelman; Wenjun Li; Steven B Richardson; Bernd H Zinselmeyer; Jiaming Lai; Mikio Okazaki; Christopher G Kornfeld; Friederike H Kreisel; Seiichiro Sugimoto; Jeremy R Tietjens; John Dempster; G Alexander Patterson; Alexander S Krupnick; Mark J Miller; Daniel Kreisel Journal: J Immunol Date: 2009-04-01 Impact factor: 5.422
Authors: Steven K Takemoto; Adriana Zeevi; Sandy Feng; Robert B Colvin; Stanley Jordan; Jon Kobashigawa; Jerzy Kupiec-Weglinski; Arthur Matas; Robert A Montgomery; Peter Nickerson; Jeffrey L Platt; Hamid Rabb; Richard Thistlethwaite; Dolly Tyan; Francis L Delmonico Journal: Am J Transplant Date: 2004-07 Impact factor: 8.086
Authors: M A Smith; S Sundaresan; T Mohanakumar; E P Trulock; J P Lynch; D L Phelan; J D Cooper; G A Patterson Journal: J Thorac Cardiovasc Surg Date: 1998-11 Impact factor: 5.209
Authors: Miae Kim; Keri R Townsend; Isabelle G Wood; Steve Boukedes; Indira Guleria; Steven Gabardi; Souheil El-Chemaly; Phillip C Camp; Anil K Chandraker; Edgar L Milford; Hilary J Goldberg Journal: Am J Respir Crit Care Med Date: 2014-05-15 Impact factor: 21.405
Authors: Yaron D Barac; Mike S Mulvihill; Oliver Jawitz; Jacob Klapper; John Haney; Mani Daneshmand; Basil Nasir; Dongfeng Chen; Carmelo A Milano; Matthew G Hartwig Journal: Ann Thorac Surg Date: 2020-04-03 Impact factor: 4.330